Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash

Overview

To evaluate whether Desitin; Zinc Oxide Diaper Rash Ointment (Desitin Original) and Desitin Creamy; Zinc Oxide Diaper Rash Ointment (Desitin Creamy) provide relief of the signs and symptoms associated with diaper rash after 12 and 24 hours of product application.

Full Title of Study: “A Parallel, Evaluator-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Two Marketed Topical Skin Protectants Containing Zinc Oxide in Children With Diaper Rash”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Care Provider, Investigator)
  • Study Primary Completion Date: October 2005

Detailed Description

Subjects received applications of the investigational products following a gentle cleansing of the diaper zone at every diaper change and following bathing of the child during a 24 hour period. Efficacy was assessed during this study through the documentation of the severity of diaper rash. Results of five anatomic areas and overall severity score by the evaluator's assessments, and parent/guardian's assessments all indicated that both products were significantly effective (P<0.05 in relieving diaper dermatitis (rash) after 12 and 24 hours of treatment. Safety was assessed through the reporting of adverse events during the course of the study. Overall, the reporting of no adverse events under the conditions of the protocol indicate that the investigational products would appear to be safe for their intended use.

Interventions

  • Other: Zinc Oxide Diaper Rash Ointment
    • Desitin Original at diaper change
  • Other: Aloe Vera/Tocopherol/Zinc Oxide Cream
    • Desitin Creamy at diaper change

Arms, Groups and Cohorts

  • Active Comparator: 1
  • Active Comparator: 2

Clinical Trial Outcome Measures

Primary Measures

  • Trained evaluator’s assessment of the severity of diaper rash and Parent/guardian’s assessment of response to treatment
    • Time Frame: At baseline and at 12 and 24 hours post-baseline

Secondary Measures

  • Adverse Events
    • Time Frame: during the course of the study

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy male and female children, 2-36 months of age – Wear diapers 24 hours per day – Present to the test facility for enrollment at baseline with diaper rash receiving an "Overall Severity Score" greater than or equal to 1.5 as determined by the trained evaluator – Parent/guardian signed informed consent – Parent/guardian willing to use only the test product in the diaper area during the trial – Parent/guardian willing to ensure that their child continues to wear their usual brand of diapers and will continue to clean their child during diaper changes using their usual products and method with the exception of ointments, lotions, creams or powders during the trial – Parent/guardian is willing to refrain from changing any other products whose use may have an effect on their child's skin condition during the trial, i.e., laundry detergents, fabric softeners, and products used to bathe the child – A Fitzpatrick Skin Type of I-IV Exclusion Criteria:

  • Illness within 4 days preceding enrollment – Currently being toilet trained – Active dermatological conditions other than diaper rash that may affect trial results – History of recurrent dermatological conditions other than diaper rash that may affect trial results – Concomitant use of medications that may affect trial results – Known sensitivity to ingredients in trial medications – Known sensitivity, rash or other abnormal skin reaction to topical or systemic medications or cleansing products within one year of trial initiation – Other severe acute or chronic medical conditions that may increase the risk associated with trial participation or may interfere with the interpretation of results

Gender Eligibility: All

Minimum Age: 2 Months

Maximum Age: 36 Months

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Johnson & Johnson Consumer and Personal Products Worldwide
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Qing Li, MD PhD, Study Director, JJCPPW

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.